This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

June 1, 2026
5 min

The Medicine Maker

Overview

VERVE-102, an investigational in vivo adenine base-editing therapy, demonstrated significant reductions in PCSK9 and LDL-C levels in a phase 1 study. No dose-limiting toxicities were reported among participants.

Background

Cholesterol management is critical in preventing cardiovascular diseases, particularly in patients with conditions like heterozygous familial hypercholesterolemia. Traditional therapies often require ongoing treatment.

Data Highlights

Parameter	Reduction
PCSK9	Up to 88%
LDL-C	Up to 62%

Key Findings

VERVE-102 is designed to inactivate PCSK9 in the liver.
The therapy was administered as a one-time treatment using mRNA in a lipid nanoparticle.
In the study, 35 participants received VERVE-102 across six dose cohorts.
No dose-limiting toxicities were reported; mild-to-moderate infusion reactions and transient liver enzyme elevations were observed.
Effects of the therapy appeared durable through follow-up of at least one year in 15 participants.

Clinical Implications

The findings suggest that VERVE-102 could offer a new therapeutic option for patients with elevated cholesterol levels, potentially reducing the need for lifelong medication. Ongoing monitoring of long-term effects and safety will be essential as this therapy progresses.

Conclusion

VERVE-102 demonstrates promising results in lowering cholesterol through a single gene-editing intervention, warranting further investigation in larger trials.